This 3-hour training will review and compare FDA’s Establishment Registration and Product Listing Requirements; and available User Fees, Fee Waivers and Marketing Exclusivity for Drugs, Biologics, Medical Devices, Food, Tobacco and Animal Health Products.
Why Should You Attend:
Almost everyone who markets and sells an FDA regulated product in the United States is required to register their facility or establishment, list their products, or both. This includes companies selling human and veterinary drugs, biologics, medical devices, foods and tobacco companies. This session will examine who must register their facilities and list their products with FDA; and how to do so.
The Prescription Drug User Fee Act commonly referred to as “PDUFA”, and The Animal Drug User Fee Act commonly referred to as “ADUFA”, authorizes FDA to collect fees from various companies that produce certain human drug and biological products; and veterinary drug products. During the course of this virtual seminar, attendees will be introduced to FDA’s assessed User Fees and when they apply. It will also discuss when and how such fees must be paid to FDA.
FDA also provides companies with several different types of Fee Waivers and Fee Reductions to lessen the financial impact on certain qualifying companies. The session will explore the fee waivers and fee reductions available to a company for each of the product specific categories; and will describe the criteria and process required for obtaining them.
There are several types of Marketing Exclusivity available to a company seeking to market and sell its products in the U.S. The presenter will discuss each of the available types of marketing exclusivity, their criteria, when they apply and their ultimate impact in the market.
Learning Objectives:
Areas Covered in the Webinar:
Who will Benefit:
Instructor Profile:
Karl Nobert, is a Food and Drug Regulatory Attorney in Washington, DC. He regularly provides FDA regulatory advice and counseling to domestic and international pharmaceutical, medical device, OTC drug, medical devices and veterinary drug companies. He advises his clients on issues related to the FDA’s regulation of their products and provides them with strategic recommendations for regulatory compliance and mitigating potential enforcement risk. He frequently presents and has published on such topics.